Use of somatostatin receptor ligands in obesity and diabetic complications

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 16, Issue 3, 2002, Pages 493-509

  Boehm, Bernhard O ^a   Lustig, Robert H ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetic retinopathy; Hyperinsulinaemia; Hypothalamic obesity; IGF system; Obesity; Somatostatin analogues; Somatostatin receptors

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPEPTIN; BM 23014; GROWTH HORMONE; OCTREOTIDE; PASIREOTIDE; PLACEBO; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; THYROXINE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; GROWTH HORMONE RELEASING FACTOR; SOMATOSTATIN RECEPTOR LIGAND;

CELL ACTIVITY; CHOLELITHIASIS; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; GROWTH HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; HYPOTHYROIDISM; INSULIN RELEASE; METABOLIC DISORDER; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS SECRETION; QUALITY OF LIFE; REVIEW; WEIGHT REDUCTION; ADIPOCYTE; CELL FUNCTION; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; HYPERINSULINEMIA; INCIDENCE; PANCREAS FUNCTION; PROLIFERATIVE RETINOPATHY; REGULATORY MECHANISM;

DIABETIC RETINOPATHY; HUMANS; OBESITY; SOMATOSTATIN;

EID: 0036595257     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2002.0320     Document Type: Article

References (104)

1. Report of a WHO Study Group, Prevention of Diabetes mellitus WHO Technical Report Series, Geneva 1994
2. Pinhas-Hamiel O Dolan L Daniels S et al. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents Journal of Pediatrics 128 1996 608-615
3. Gerich J E Lorenzi M Schneider V et al. Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications New England Journal of Medicine 291 1974 544-547
4. Lamberts S WJ van Der Lely A J De Herder W W et al. Drug therapy: octreotide New England Journal of Medicine 334 1996 246-254
5. Feldmann B Jehle P M Mohan S et al. Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF-binding proteins Growth Hormone & IGF Research 10 2000 53-60
6. Smith L E Kopchick J J Chen W et al. Essential role of growth hormone in ischemia-induced retinal neovascularization Science 276 1997 1706-1709
7. Poulsen S E The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmond's disease Diabetes 2 1953 7-12
8. Krulich L Dhariwal A PS McCann S M Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro Endocrinology 83 1968 783
9. Brazeau P Vale W Burgus R et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone Science 179 1972 77
10. Yamada Y Post S R Wang K et al. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney Proceedings of the National Academy of Sciences of the USA 89 1992 251-255
11. Yamada Y Reisine T Law S F et al. Somatostatin receptors, an expanding gene family: cloning and functional characterization on human SSTR3, a protein coupled to adenly cyclase Molecular Endocrinology 6 1992 2136-2142
12. Raulf F Perez J Hoyer D Bruns C Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue Digestion 55 1994 (s) 46-53
13. Patel Y C Molecular pharmacology of somatostatin receptors subtypes Journal of Endocrinological Investigation 20 1997 348-367
14. Hoyer D Lübbert H Bruns C Molecular pharmacology of somatostatin receptors Naunyn-Schmiedeberg's Archives of Pharmacology 350 1994 441-453
15. van Hagen P M Baarsma G S Mooy C M et al. Somatostatin and somatostatin receptors in retinal diseases European Journal of Endocrinology 143 2000 S43-S51
16. Bruns, C, Lewis, I, Briner, U, Weckbecker, G, SOM230: a new somatostatin peptidomimetic with unique binding and endocrine profile. Endocrine Society Meeting, Denver CO 2001 (abstract)
17. Rohrer S P Birzin E T Mosley R T et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry Science 282 1998 737-740
18. Report of a WHO Consultation Definition, diagnosis and classification of diabetes mellitus and its complications 1999 World Health Organization, Geneva
19. Klein R The epidemiology of eye disease In Pickup J C Williams G (Eds.), Textbook of Diabetes 1997 44.1-44.9 Blackwell Sciences Oxford
20. Kohner E M Diabetic retinopathy British Medical Journal 307 1993 1195-1199
21. Klein R Klein B EK Moss S E Cruickshanks K J The Wisconsin Epidemiologic study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy Archives of Ophthalmology 112 1994 1217-1228
22. The Diabetes Control and Complications Trial Research Group, The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy New England Journal of Medicine 342 2000 381-389
23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837-853
24. DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45 1996 1289-1298
25. UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes Lancet 352 1998 837-853
26. Stratton I M Adler A I Neil H A et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study British Medical Journal 321 2000 405-412
27. Poulsen S E Diabetes and anterior pituitary insufficiency: final course and postmortem study of a diabetic patient with Sheehan's syndrome Diabetes 15 1966 73-77
28. Dawson D W Volpert O V Gillis P et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis Science 285 1999 245-248
29. Stellmach V Crawford S E Zhou W Bouck N Prevention of ischemia induced retinopathy by the natural ocular anti-angiogenic agent pigment epithelium-derived factor Proceedings of the National Academy of Sciences of the USA 98 2001 2593-2597
30. Aiello L P Avery R L Arrigg P G et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders New England Journal of Medicine 331 1994 1480-1487
31. Aiello L P Pierce E A Foley E D et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins Proceedings of the National Academy Sciences of the USA 92 1995 10457-10461
32. Kohner E M Hamilton A M Joplin G F Fraser T R Florid diabetic retinopathy and its response to treatment by photocoagulation or pituitary ablation Diabetes 25 1976 104-110
33. Boehm B O Treatment of diabetic retinopathy with long-acting somatostatin analogues In Lamberts S WJ (Ed.) Octreotide: The next decade, 1999 241-257 BioScientifica Ltd Bristol
34. Kujipers R WAM Baarsma G S van Hagen P M Treatment of cystoid macular edema with octreotide New England Journal of Medicine 338 1998 624-626
35. Grant M B Mames R N Fitzgerald C et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative retinopathy. A randomized controlled study Diabetes Care 23 2000 504-509
36. Shternfeld I S Chambers R B O'Dorisio T M et al. The effect of octreotide on ocular proliferative disease: a pilot study Investigation Ophthalmology and Visual Science 40 1999 S70
37. Boehm B O Lang G K Jehle P M et al. Octreotide reduces risk for vitreous hemorrhages and loss of visual acuity in patients with high risk proliferative diabetic retinopathy Hormone Metabolic Research 33 2001 300-306
38. Suzuma I Hata Y Clermont A et al. Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension Diabetes 50 2001 444-454
39. Adamis A P Miller J W Bdernal M-T et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy American Journal of Ophthalmology 118 1994 445-450
40. Lawnicka H Stepien H Wyczolkowaska J et al. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECCa10) culture Biochemical and Biophysical Research Communications 268 2000 567-571
41. Demir T Celiker U O Kukner A et al. Effect of octreotide on experimental corneal neovascularization Acta Ophthalmologica Scandinavica 77 1999 386-390
42. Mokdad A H Serdula M K Dietz W H et al. The spread of the obesity epidemic in the United States. 1991-1998 Journal of the American Medical Association 282 1999 1519-1522
43. Lustig R H The neuroendocrinology of obesity Endocrinology and Metabolism Clinics of North America 30 2001 765-785
44. Bray G A Gallagher T F Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature Medicine 54 1975 301-333
45. York D A Lessons from animal models of obesity Endocrinology and Metabolism Clinics of North America 25 1996 781-800
46. Marin P Russeffé-Scrive A Smith J Bjorntorp P Glucose uptake in human adipose tissue Metabolism 36 1988 1154-1164
47. Ramsay T G Fat cells Endocrinology and Metabolism Clinics of North America 25 1996 847-870
48. Lillioja S Nyomba B Saad M et al. Exaggerated early insulin release and insulin resistance in a diabetes-prone population: a metabolic comparison of Pima Indians and caucasians Journal of Clinical Endocrinology and Metabolism 73 1991 866-876
49. Haffner S M D'Agostino R Saad M F et al. Increased insulin resistance and insulin secretion in non-diabetic African-Americans and Hispanics compared with non-Hispanic whites: the insulin resistance atherosclerosis study Diabetes 45 1996 742-748
50. Postic C Burcelin R Rencurel F et al. Evidence for a transient inhibitory effect of insulin of GLUT2 expression in the liver: studies in vivo and in vitro Biochemical Journal 293 1993 119-124
51. Thorens B Flier J S Lodish H F Kahn B B Differential regulation of two glucose transporters in rat liver by fasting and refeeding and by diabetes and insulin treatment Diabetes 39 1990 712-719
52. Kolterman O G Reaven G M Olefsky J M Relationship between in vivo insulin resistance and decreased insulin receptors in obese man Journal of Clinical Endocrinology and Metabolism 48 1979 487-494
53. Knutson V P Proteolytic processing of the insulin receptor beta subunit is associated with insulin-induced receptor down-regulation Journal of Biological Chemistry 266 1991 15656-15662
54. Silverman B L Landsberg L Metzger B E Fetal hyperinsulinism in offspring of diabetic mothers: association with the subsequent development of childhood obesity Annals of the New York Academy of Sciences 699 1993 36-45
55. Krew M A Kehl R J Thomas A Catalano P M Relation of amniotic fluid C-peptide levels to neonatal body composition Obstetrics and Gynecology 84 1994 96-100
56. Reaven G M Pathophysiology of insulin resistance in human disease Physiological Reviews 75 1995 473-486
57. Assimacopoulos-Jeannet F Brichard S Rencurel F et al. In vivo effects of hyperinsulinemia on lipogenic enzymes and glucose transporter expression in rat liver and adipose tissues Metabolism 44 1995 228-233
58. Barakat H A Mooney N O'Brien K et al. Coronary heart disease risk factors in morbidly obese women with normal glucose tolerance Diabetes Care 16 1993 144-149
59. Bonadonna R C Groop L Kraemer N Obesity and insulin resistance in humans: a dose response study Metabolism 39 1990 452-459
60. Ravussin E Swinburn B A Insulin resistance is a result, not a cause of obesity: Socratic debate: the pro side In Angel A et al. (Ed.), Progress in Obesity Research, 1996 173-178 Libbey London
61. Sims E AH Insulin resistance is a result, not a cause of obesity: Socratic debate: the con side In Angel A et al. (Ed.) Progress in Obesity Research, 1996 587-592 Libbey London
62. Campfield L A Smith F J Mackie G et al. Insulin normalization as an approach to the pharmacological treatment of obesity Obesity Research 3 1995 591S-603S
63. Sigal R J El-Hashimy M Martin B C et al. Acute post-challenge hyperinsulinemia predicts weight gain Diabetes 46 1997 1025-1029
64. LeStunff C Bougneres P Early changes in postprandial insulin secretion, not in insulin sensitivity, characterize juvenile obesity Diabetes 43 1994 696-702
65. Jeanrenaud B An hypothesis on the aetiology of obesity: dysfunction of the central nervous system as a primary cause Diabetologia 28 1985 502-513
66. Sorva R Children with craniopharyngioma: early growth failure and rapid post-operative weight gain Acta Pediatrica Scandinavica 77 1988 587-592
67. Satoh N Ogawa Y Katsura G et al. Pathophysiological significance of the obese gene product, leptin in ventromedial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in VMH-lesioned rats Endocrinology 138 1997 947-954
68. Bray G A York D A Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis Physiological Reviews 59 1979 719-809
69. Gilon P Henquin J C Mechanisms and physiological significance of the cholinergic control of pancreatic β-cell function Endocrine Reviews 22 2001 565-604
70. Ionescu E Rohner-Jeanrenaud F Berthoud H R Jeanrenaud B Increases in plasma insulin levels in response to electrical stimulation of the dorsal motor nucleus of the vagus nerve Endocrinology 112 1983 904-910
71. Berthoud H R Jeanrenaud B Acute hyperinsulinemia and its reversal by vagotomy following lesions of the ventromedial hypothalamus in anesthetized rats Endocrinology 105 1979 146-151
72. Tokunaga K Fukushima M Kemnitz J W Bray G A Effect of vagotomy on serum insulin in rats with paraventricular or ventromedial hypothalamic lesions Endocrinology 119 1986 1708-1711
73. Inoue S Bray G A The effect of subdiaphragmatic vagotomy in rats with ventromedial hypothalamic lesions Endocrinology 100 1997 108-114
74. 2+ pools Biochemical and Biophysical Research Communications 224 1996 67-73
75. Zawalich W S Zawalich K C Rasmussen H Cholinergic agonists prime the β-cell to glucose stimulation Endocrinology 125 1989 2400-2406
76. Rohner-Jeanrenaud F Jeanrenaud B Involvement of the cholinergic system in insulin and glucagon oversecretion of genetic preobesity Endocrinology 116 1985 830-834
77. Tian Y M Urquidi V Ashcroft S JH Protein kinase C in β-cells: expression of multiple isoforms and involvement in cholinergic stimulation of insulin secretion Molecular and Cellular Endocrinology 119 1996 185-193
78. 2+ store in secretory granules of insulin-producing cells Journal of Biological Chemistry 269 1994 27167-27170
79. Kiefer T J Habener J F The glucagon-like peptides Endocrine Reviews 20 1999 876-913
80. Rocca A S Brubaker P L Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion Endocrinology 140 1999 1687-1694
81. Mitra S W Mezey E Hunyady B Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic β-cells Endocrinology 140 1999 3790-3796
82. Gordon D F Woodmansee W W Lewis S R et al. Cloning of the mouse somatostatin receptor subtype 5 gene: promoter structure and function Endocrinology 140 1999 5598-5608
83. 2+ channels in the beta-cell Journal of Biological Chemistry 266 1991 837-843
84. Giustina A Bussi A R Pizzocolo G et al. Acute effects of octreotide, a long-acting somatostatin analog, on the insulinemic and glycemic responses to a mixed meal in patients with essential obesity: a dose-response study Diabetes, Nutrition, and Metabolism 7 1994 35-41
85. Rohner-Jeanrenaud F Jeanrenaud B Consequences of ventromedial hypothalamic lesions upon insulin and glucagon secretion by subsequently isolated perfused pancreases in the rat Journal of Clinical Investigation 65 1980 902-910
86. Bray G A Inoue S Nishizawa Y Hypothalamic obesity Diabetologia 20 1981 366-377
87. Bray G A Syndromes of hypothalamic obesity in man Pediatric Annals 13 1984 525-536
88. Lustig R H Hypothalamic obesity: the sixth cranial endocrinopathy Endocrinologist 2002 (in press)
89. Stahnke N Grubel G Lagenstein I Willig R P Long-term follow-up of children with craniopharyngioma European Journal of Pediatrics 142 1984 179-185
90. Pinto G Bussieres L Recasens C et al. Hormonal factors influencing weight and growth pattern in craniopharyngioma Hormone Research 53 2000 163-169
91. Bray G A Nishizawa Y Ventromedial hypothalamus modulates fat mobilization during fasting Nature 274 1978 900-902
92. Lustig R H Rose S R Burghen G A et al. Hypothalamic obesity in children caused by cranial insult: altered glucose and insulin dynamics, and reversal by a somatostatin agonist Journal of Pediatrics 135 1999 162-168
93. Lustig, R, H, Hinds, P, S, Smith, K, R, et al. A double-blind, placebo-controlled trial of octreotide in pediatric hypothalamic obesity 6th Lawson Wickins Pediatric Society/European Pediatric Endocrine Society meeting, 2001 (abstract)
94. Velasquez-Mieyer, P, A, Buffington, C, K, Arheart, K, L, et al. Primary insulin hypersecretion: a specific and remediable subtype of obesity 11th International Congress of Endocrinology 2000 p 1054 (abstract)
95. Cashion, A, K, Velasquez-Mieyer, PA, Arheart, K, L, et al. Correlations between autonomic function, β-cell activity, insulin sensitivity, and glucose tolerance in obesity 11th International Congress of Endocrinology 2000 p 1056
96. Simsolo R B Ezzat S Ong J M et al. Effects of acromegaly treatment and growth hormone on adipose tissue lipoprotein lipase Journal of Clinical Endocrinology and Metabolism 80 1995 3233-3238
97. Lotter E C Krinsky R McKay J M et al. Somatostatin decreases food intake of rats and baboons Journal of Comparative and Physiological Psychology 95 1981 278-287
98. Levine A S Morley J E Peripherally administered somatostatin reduces feeding by a vagal mediated mechanism Pharmacology, Biochemistry, and Behavior 16 1982 897-902
99. Simón M A Romero B Calle C Characterization of somatostatin binding sites in isolated rat adipocytes Regulatory Peptides 23 1988 261-270
100. Campbell R M Scanes C G Inhibition of growth hormone-stimulated lipolysis by somatostatin, insulin, and insulin-like growth factors (somatomedins) in vitro Proceedings of the Society for Experimental Biology and Medicine 189 1988 362-366
101. Jiminez J Zuniga-Guajardo S Zinman B Angel A Effects of weight loss in massive obesity on insulin and C-peptide dynamics: sequential changes in insulin production, clearance, and sensitivity Journal of Clinical Endocrinology and Metabolism 64 1987 661-668
102. Hansen T B Gram J Bjerre P et al. Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study Clinical Endocrinology 41 1994 323-329
103. Luft R Guillemin R Growth hormone and diabetes in man. Old concepts - new implications Diabetes 23 1974 783-787
104. Gerich J E Lorenzi M Schneider V et al. Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and in insulin-dependent diabetics Diabetes 23 1974 876-880